A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of TAK-831 in Healthy Subjects

The purpose of this study is to determine the safety, tolerability and pharmacokinetics (PK) of single and multiple rising doses of TAK-831 in healthy participants.

Study Overview

• Status: Terminated
• Conditions: Schizophrenia, Cerebellar Ataxia
• Intervention / Treatment: Drug: TAK-831 Oral Suspension; Drug: TAK-831 Placebo; Drug: TAK-831 Tablet

Detailed Description

The drug being tested in this study is called TAK-831. TAK-831 is being tested to treat participant who have schizophrenia and cerebellar ataxia. This study will look at the PK, safety and tolerability of TAK-831 in healthy participants. The study will enroll approximately 120 participants. The study will include 4 parts: Part 1 (single-rising dose [SRD]), Part 2 (SRD/multiple-rising dose [MRD]), Part 3 (MRD) and Part 4 (relative bioavailability study). Participants will be randomly assigned (by chance, like flipping a coin) to receive either active drug TAK-831 or placebo which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):

• Part 1, Cohort 1: single dose of TAK-831 100 mg
• Part 1, Cohort 2: single dose of TAK-831 250 mg
• Part 1, Cohort 3: single dose of TAK-831 500 mg
• Part 1, Cohort 4: single dose of TAK-831 30 mg
• Part 1, Cohort 5: single dose of TAK-831 750 mg
• Part 1, Cohort 6: single dose of TAK-831 10 mg
• Part 2, Cohort 1: single dose of TAK-831 30 mg
• Part 2, Cohort 2: single dose of TAK-831 100 mg
• Part 2, Cohort 3: single dose of TAK-831 200 mg
• Part 2, Cohort 4: single dose of TAK-831 400 mg
• Part 3, Cohort 1: TAK-831 400 mg
• Part 4: TAK-831 100 mg (Tablet Fasted + Tablet Fed + Suspension Fasted)
• Part 4: TAK-831 100 mg (Tablet Fed + Tablet Fasted + Suspension Fasted)
• Part 4: TAK-831 100 mg (Suspension Fasted+ Tablet Fed + Tablet Fasted)

Dosing with TAK-831 will progress into study Part 2, 3 and 4, only after review of all available safety, tolerability, and PK data collected in Cohorts 1 to 6 of the Study Part 1. This single center trial will be conducted in the United Kingdom. The overall time to participate in this study is approximately up to 58 days. Participants will be admitted in the clinic for the up to 20 days, and will be contacted by telephone 14 days after last dose of study drug for a follow-up assessment.

The study was terminated by Takeda due to the discomfort observed in the study participants from the CSF collection procedure in Part 3 of the study, hence it is was not feasible to collect further CSF samples that were required to meet the exploratory objectives of the study. Part 1, 2 and 4 of the study were completed as planned.

• Study Type: Interventional
• Enrollment (Actual): 110
• Phase: Phase 1

Contacts and Locations

Study Locations

• United Kingdom
  • London, United Kingdom

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Should be capable of understanding and complying with protocol requirements.
2. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
3. Healthy male or female aged between 18 to 55 years- Weighing at least 45 kilogram (kg) and has a body mass index (BMI) from 18.0 to 30.0 kilogram per square meter (kg/m^2).
4. Male participant who is nonsterilized and sexually active with a female partner of childbearing potential agrees to use adequate contraception from signing of informed consent throughout the duration of the study and for 12 weeks after last dose.
5. Female participant with no childbearing potential, defined as a participant that has been surgically sterilized (hysterectomy, bilateral oophorectomy or tubal ligation) or who is post menopausal (defined as continuous amenorrhea of at least 2 years and follicle-stimulating hormone [FSH] greater than [>] 40 international units per liter [IU/L]).

Exclusion Criteria:

1. Received any investigational compound within 3 months prior to randomization.
2. Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in the conduct of this study (example, spouse, parent, child, sibling) or may consent under duress.
3. Has uncontrolled, clinically significant neurological (including seizure disorders), cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, endocrine disease, or psychiatric disorder, or other abnormality.
4. Has a known hypersensitivity to any component of the formulation of TAK-831.
5. Female participant is of childbearing potential.
6. Has a positive urine drug result for drugs of abuse (defined as any illicit drug use) at Screening or Check-in.
7. History of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 1 year prior to the Screening visit or is unwilling to agree to abstain from alcohol and drugs throughout the study. One unit is equivalent to a half-pint of beer or 1 single measure of spirits or 1 small glass of wine.
8. Has taken any excluded medication, supplements, or food products during the time periods listed in the excluded medications and dietary products.
9. Female participant is pregnant or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate ova during such time period.
10. Male participant intending to donate sperm during the course of this study or for 12 weeks after the last dose of study medication.
11. Has evidence of current cardiovascular, central nervous system, hepatic, hematopoietic disease, renal dysfunction, metabolic or endocrine dysfunction, serious allergy, asthma, hypoxemia, hypertension, seizures, or allergic skin rash.
12. Has a QT interval with Fridericia's correction method (QTcF) >450 millisecond (msec) (males) or >470 msec (females) or PR outside the range of 120 to 220 msec, confirmed with one repeat testing, at the screening visit or check-in (Day -2).
13. Has current or recent (within 6 months) gastrointestinal disease that would be expected to influence the absorption of drugs (that is, a history of malabsorption, esophageal reflux, peptic ulcer disease, erosive esophagitis, frequent [more than once per week] occurrence of heartburn, or any surgical intervention.
14. Has a history of cancer, except basal cell carcinoma which has been in remission for at least 5 years prior to Day 1.
15. Has a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antibody/antigen at Screening.
16. Has used nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patch or nicotine gum) within 28 days prior to Check-in. Cotinine test is positive at Screening or Check-in.
17. Has poor peripheral venous access.
18. Has donated or lost 450 milliliter (mL) or more of his or her blood volume (including plasmapheresis), or had a transfusion of any blood product within 45 days prior to first dose of medication.
19. Has a Screening or Check-in abnormal (clinically significant) electrocardiogram (ECG). Entry of any participant with an abnormal (not clinically significant) ECG must be approved, and documented by signature by the principal investigator or designee.
20. Has a supine blood pressure outside the ranges of 90 to 140 millimeter of mercury (mm Hg) for systolic and 50 to 90 mm Hg for diastolic, confirmed on repeat testing within a maximum of 30 minutes, at the Screening Visit or Check-in.
21. Has a resting heart rate outside the range 40 to 100 bpm confirmed on repeat testing within a maximum of 30 minutes, at the Screening Visit or Check-in.
22. Has abnormal Screening or check-in laboratory values that suggest a clinically significant underlying disease or participant with the following lab abnormalities: Alanine transaminase (ALT) and/or aspartate aminotransferase (AST) >1.5 the upper limits of normal.
23. Has a risk of suicide according to the Investigator's clinical judgment (example, per The Columbia Suicide Severity Rating Scale [C-SSRS]), or has scored "yes" on item 4 or item 5 of the Suicidal Ideation section of the C-SSRS, if this ideation occurred in the past 6 months, or "yes" on any item of the Suicidal Behavior section, except for the "Non-Suicidal Self-Injurious Behavior", if this behaviour occurred in the past 2 years.
24. Has received TAK-831 in a previous clinical study.
25. Participant is vegan or vegetarian (Part 4 only - food effect).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: OTHER
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: DOUBLE

Number of Arms

14

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Part 1, Cohort 1: TAK-831 100 mg; TAK-831 100 milligram (mg), suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.	Drug: TAK-831 Oral Suspension; TAK-831 oral suspension.; Drug: TAK-831 Placebo; TAK-831 placebo-matching oral suspension.
EXPERIMENTAL: Part 1, Cohort 2: TAK-831 250 mg; TAK-831 250 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.	Drug: TAK-831 Oral Suspension; TAK-831 oral suspension.; Drug: TAK-831 Placebo; TAK-831 placebo-matching oral suspension.
EXPERIMENTAL: Part 1, Cohort 3: TAK-831 500 mg; TAK-831 500 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.	Drug: TAK-831 Oral Suspension; TAK-831 oral suspension.; Drug: TAK-831 Placebo; TAK-831 placebo-matching oral suspension.
EXPERIMENTAL: Part 1, Cohort 4: TAK-831 30 mg; TAK-831 30 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.	Drug: TAK-831 Oral Suspension; TAK-831 oral suspension.; Drug: TAK-831 Placebo; TAK-831 placebo-matching oral suspension.
EXPERIMENTAL: Part 1, Cohort 5: TAK-831 750 mg; TAK-831 750 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.	Drug: TAK-831 Oral Suspension; TAK-831 oral suspension.; Drug: TAK-831 Placebo; TAK-831 placebo-matching oral suspension.
EXPERIMENTAL: Part 1, Cohort 6: TAK-831 10 mg; TAK-831 10 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.	Drug: TAK-831 Oral Suspension; TAK-831 oral suspension.; Drug: TAK-831 Placebo; TAK-831 placebo-matching oral suspension.
EXPERIMENTAL: Part 2, Cohort 1: TAK-831 30 mg; TAK-831 30 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.	Drug: TAK-831 Oral Suspension; TAK-831 oral suspension.; Drug: TAK-831 Placebo; TAK-831 placebo-matching oral suspension.
EXPERIMENTAL: Part 2, Cohort 2: TAK-831 100 mg; TAK-831 100 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.	Drug: TAK-831 Oral Suspension; TAK-831 oral suspension.; Drug: TAK-831 Placebo; TAK-831 placebo-matching oral suspension.
EXPERIMENTAL: Part 2, Cohort 3: TAK-831 200 mg; TAK-831 200 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.	Drug: TAK-831 Oral Suspension; TAK-831 oral suspension.; Drug: TAK-831 Placebo; TAK-831 placebo-matching oral suspension.
EXPERIMENTAL: Part 2, Cohort 4: TAK-831 400 mg; TAK-831 400 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.	Drug: TAK-831 Oral Suspension; TAK-831 oral suspension.; Drug: TAK-831 Placebo; TAK-831 placebo-matching oral suspension.
EXPERIMENTAL: Part 3, Cohort 1: TAK-831 400 mg; TAK-831 400 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once daily from Days 1 to 14.	Drug: TAK-831 Oral Suspension; TAK-831 oral suspension.; Drug: TAK-831 Placebo; TAK-831 placebo-matching oral suspension.
EXPERIMENTAL: Part 4:TAK-831(Tablet Fasted+ Tablet Fed + Suspension Fasted); TAK-831 100 mg, tablet, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 1, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once 30 minutes after starting a high fat meal on Day 1 of Period 2, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, suspension, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 3.	Drug: TAK-831 Oral Suspension; TAK-831 oral suspension.; Drug: TAK-831 Tablet; TAK-831 tablet.
EXPERIMENTAL: Part 4:TAK-831(Tablet Fed + Tablet Fasted + Suspension Fasted); TAK-831 100 mg, tablet, orally, once 30 minutes after starting a high fat meal on Day 1 of Period 1, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 2, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, suspension, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 3.	Drug: TAK-831 Oral Suspension; TAK-831 oral suspension.; Drug: TAK-831 Tablet; TAK-831 tablet.
EXPERIMENTAL: Part 4:TAK-831(Suspension Fasted+ Tablet Fed + Tablet Fasted); TAK-831 100 mg, suspension, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 1, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once 30 minutes after starting a high fat meal on Day 1 of Period 2, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 3.	Drug: TAK-831 Oral Suspension; TAK-831 oral suspension.; Drug: TAK-831 Tablet; TAK-831 tablet.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)		Baseline up to 30 days after the last dose of study drug (Part 1 Day 31, Part 2 Day 46, Part 3 Day 44 and Part 4 Day 43)
Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post Dose	Clinical laboratory tests included hematology, serum chemistry and urinalysis.	Baseline up to Day 15 in Part 1, Day 30 in Part 2, Day 28 in Part 3 and Day 25 in Part 4
Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post Dose	Markedly abnormal criteria for vital signs measurement was assessed. The lower criteria and upper criteria for abnormality are as follow: systolic blood pressure at less than (<) 85 millimeter of mercury (mm Hg) to greater than (>) 180 mm Hg; diastolic blood pressure < 50 mm Hg to >110 mm Hg; pulse rate <50 bpm to >120 bpm; Temperature <35.6 degree Celsius to >37.7 degree Celsius.	Baseline up to Day 15 in Part 1, Day 30 in Part 2, Day 28 in Part 3 and Day 25 in Part 4
Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) Parameters at Least Once Post Dose	Markedly abnormal criteria for ECG was assessed. The lower cut-off point criteria and upper cut-off point criteria are as follow: heart rate <50 beats per minute (bpm) to >120 bpm; PR interval less than or equal to (<=) 80 millisecond (msec) to greater than or equal to (>=) 200 msec; QRS interval <=80 msec to >=180 msec; QT interval <=300 msec to >=460 msec; QTcB interval <=300 msec to >=500 msec or >=30 msec change from baseline and >=450 msec; QT interval with Fridericia's correction method (QTcF) interval <=50 msec to >=500 msec or >=30 msec change from baseline and >=450 msec.	Baseline up to Day 15 in Part 1, Day 30 in Part 2, Day 28 in Part 3 and Day 25 in Part 4

Secondary Outcome Measures

Outcome Measure	Time Frame
Part 1, 2 and 4: Cmax: Maximum Observed Plasma Concentration for TAK-831	Day 1 pre-dose and at multiple time points (up to 96 hours in Part 1 and up to 72 hours in Part 2 and 4) post-dose
Part 2 and 3: Cmax, ss: Maximum Observed Plasma Concentration at Steady State for TAK-831	Day 16 (Part 2) and Day 14 (Part 3) pre-dose and at multiple time points (up to 24 hours) post-dose
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-831	Day 1 pre-dose and at multiple time points (up to 96 hours in Part 1 and up to 72 hours in Part 2 and 4) post-dose; Day 16 (Part 2) and Day 14 (Part 3) pre-dose and at multiple time points (up to 24 hours) post-dose
Part 1, 2 and 4: AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-831	Day 1 pre-dose and at multiple time points (up to 96 hours in Part 1 and up to 72 hours in Part 2 and 4) post-dose
Part 1, 2 and 4: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-831	Day 1 pre-dose and at multiple time points (up to 96 hours in Part 1 and up to 72 hours in Part 2 and 4) post-dose
Part 2 and 3: AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for TAK-831	Day 16 (Part 2) and Day 14 (Part 3) pre-dose and at multiple time points (up to 24 hours) post-dose

Collaborators and Investigators

• Sponsor: Neurocrine Biosciences
• Collaborators: Takeda

Study record dates

Study Major Dates

• Study Start: September 23, 2015
• Primary Completion (ACTUAL): June 9, 2016
• Study Completion (ACTUAL): July 12, 2016

Study Registration Dates

• First Submitted: October 1, 2015
• First Submitted That Met QC Criteria: October 1, 2015
• First Posted (ESTIMATE): October 2, 2015

Study Record Updates

• Last Update Posted (ACTUAL): June 14, 2021
• Last Update Submitted That Met QC Criteria: June 9, 2021
• Last Verified: June 1, 2021

More Information

Terms related to this study

• Keywords: Drug therapy
• Additional Relevant MeSH Terms: Mental Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurologic Manifestations; Schizophrenia Spectrum and Other Psychotic Disorders; Dyskinesias; Cerebellar Diseases; Schizophrenia; Ataxia; Cerebellar Ataxia
• Other Study ID Numbers: TAK-831-1001; 2015-002295-24 (EUDRACT_NUMBER); U1111-1168-6568 (REGISTRY: WHO); 15/SC/0412 (REGISTRY: NRES)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO